Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jun 1, 2026

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

miRNA expression in diffuse large B-cell lymphoma treated with chemoimmunotherapy.

Santiago Montes-Moreno1, Nerea Martinez, Beatriz Sanchez-Espiridión

  • 1Lymphoma Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.

Blood
|June 3, 2011
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Rituximab Maintenance Added to Ibrutinib-Containing Therapy in Younger, Untreated Patients With Mantle Cell Lymphoma: Results From the TRIANGLE Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

A pilot translational study of neoadjuvant fulvestrant plus abemaciclib in women with advanced low-grade serous carcinoma.

Nature communications·2026
Same author

BTK Degraders in Lymphoid Malignancies: New Modality, New Resistance Rules?

Blood cancer discovery·2026
Same author

PET-guided early identification of CAR-T candidates in diffuse large b-cell lymphoma: a multidisciplinary expert consensus.

European journal of nuclear medicine and molecular imaging·2026
Same author

Retraction Note: MEK1/2 regulate normal BCR and ABL1 tumor-suppressor functions to dictate ATO response in TKI-resistant Ph+ leukemia.

Leukemia·2026
Same author

Application of Hi-C sequencing to detect oncogene rearrangements for diagnosis and treatment of large B-cell lymphoma.

Blood advances·2026

MicroRNAs (miRNAs) can predict outcomes in diffuse large B-cell lymphoma (DLBCL) patients treated with chemoimmunotherapy. A specific miRNA signature improves prognostic accuracy beyond the standard IPI score, identifying high-risk patients for alternative treatments.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Prognosticating diffuse large B-cell lymphoma (DLBCL) necessitates advanced biologic markers beyond current clinical assessments.
  • MicroRNAs (miRNAs) show potential as biomarkers for cancer diagnosis, prognosis, and therapeutic response.

Purpose of the Study:

  • To investigate miRNA expression profiles in DLBCL patients treated with chemoimmunotherapy.
  • To determine if miRNA signatures can improve the prediction of overall survival (OS) and progression-free survival (PFS).
  • To develop predictive models incorporating miRNA expression and clinical variables like the International Prognostic Index (IPI).

Main Methods:

  • Retrospective analysis of miRNA expression in 258 DLBCL patients using microarrays and multiplex RT-PCR.

More Related Videos

Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy
09:40

Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy

Published on: October 4, 2019

Evaluation of Tumor-infiltrating Leukocyte Subsets in a Subcutaneous Tumor Model
07:49

Evaluation of Tumor-infiltrating Leukocyte Subsets in a Subcutaneous Tumor Model

Published on: April 13, 2015

Related Experiment Videos

Last Updated: Jun 1, 2026

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy
09:40

Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy

Published on: October 4, 2019

Evaluation of Tumor-infiltrating Leukocyte Subsets in a Subcutaneous Tumor Model
07:49

Evaluation of Tumor-infiltrating Leukocyte Subsets in a Subcutaneous Tumor Model

Published on: April 13, 2015

  • Correlation of miRNA profiles with OS and PFS.
  • Development and validation of Cox regression models using training (123 patients) and independent validation (117 patients) sets.

    • Main Results:

    • A distinct miRNA signature was identified and associated with poor clinical outcomes in DLBCL.
    • miRNA-based models demonstrated improved prediction of OS and PFS compared to clinical variables alone.
    • Combined models integrating miRNA signature and IPI score identified a high-risk subgroup with significantly worse survival probabilities.

    Conclusions:

    • A specific miRNA signature serves as a potent prognostic biomarker in chemoimmunotherapy-treated DLBCL.
    • This miRNA signature enhances the predictive power of the IPI score.
    • Identification of high-risk patients via miRNA profiling may guide selection for alternative therapeutic strategies.